Uric acid as a cardiorenal mediator: pathogenesis and mechanistic insights

References

• Huang W-M, Hsu P-F, Cheng H-M, et al. Determinants and prognostic impact of hyperuricemia in hospitalization for acute heart failure. Circ J. 2016;80(2):404–410.
   PubMed Web of Science ®Google Scholar
• Khan A, Shah MH, Khan S, et al. Serum uric acid level in the severity of Congestive Heart Failure (CHF). Pakistan J Med Sci. 2017;33:330–334.
   PubMed Web of Science ®Google Scholar
• Tsai C-W, Lin S-Y, Kuo -C-C, et al. Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review. PLoS One. Internet]. 2017;12:e0170393–e0170393.
   PubMed Web of Science ®Google Scholar
• Roch-Ramel F, Guisan B. Renal transport of urate in humans. 1999;14:80–84. News Physiol Sci an Int J Physiol Prod jointly by Int Union Physiol Sci Am Physiol Soc.
   Google Scholar
• Taskinen M-R, Packard CJ, Borén J, Dietary fructose and the metabolic syndrome. Nutrients. Internet]. 2019;11(9):1987. Available from.
   PubMed Web of Science ®Google Scholar
• Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest. 2005;115(3):500–508.
   PubMed Web of Science ®Google Scholar
• Waring WS, Webb DJ, Maxwell SR. Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol. 2001;38(3):365–371.
   PubMed Web of Science ®Google Scholar
• Estevez-Garcia IO, Gallegos-Nava S, Vera-Pérez E, et al. Levels of cytokines and micro RNAs in individuals with asymptomatic hyperuricemia and ultrasonographic findings of gout: a bench-to-bedside approach. Arthritis Care Res (Hoboken). 2018;70(12):1814–1821. .
   PubMed Web of Science ®Google Scholar
• Bruns A, Turnbull CHS, Dolnicar D, et al. Scholar (10). Internet]. Mass Commun Soc. 1974. p. 349–383. Available from. : http://www.sciencedirect.com/science/article/pii/S0160738315000444
   Google Scholar
• Hamid T, Guo SZ, Kingery JR, et al. Cardiomyocyte NF-κB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. Cardiovasc Res. 2011;89(1):129–138. Internet]. Available from.
   PubMed Web of Science ®Google Scholar
• Houston M, Estevez A, Chumley P, et al. Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J Biol Chem. 1999;274:4985–4994.
   PubMed Web of Science ®Google Scholar
• Wang J, Qin T, Chen J, et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS One. 2014;9(12):e114259.
   PubMed Web of Science ®Google Scholar
• Sánchez-Lozada LG, Lanaspa MA, Cristóbal-García M, et al. Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. Nephron Exp Nephrol. 2012;121(3–4):e71–8.
   PubMedGoogle Scholar
• Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282(6):F991–7.
   PubMed Web of Science ®Google Scholar
• Pan K-L, Lin J-C, Lin C-L, et al. The effects of gout on left atrial volume remodelling: a prospective echocardiographic study. Rheumatology (Oxford). 2014;53(5):867–874.
   PubMed Web of Science ®Google Scholar
• Mitsuhashi H, Yatsuya H, Matsushita K, et al. Uric acid and left ventricular hypertrophy in Japanese men. Circ J. 2009;73(4):667–672.
   PubMed Web of Science ®Google Scholar
• Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Physiol. 2001;280(1):C53–C60.
   PubMed Web of Science ®Google Scholar
• Piepoli MF, Salvioni E, Corrà U, et al. Increased serum uric acid level predicts poor prognosis in mildly severe chronic heart failure with reduced ejection fraction. An analysis from the MECKI score research group. Eur J Intern Med. 2020;72:47–52.
   PubMed Web of Science ®Google Scholar
• Huang G, Qin J, Deng X, et al. Prognostic value of serum uric acid in patients with acute heart failure: a meta-analysis. Medicine (Baltimore). 2019;98(8):e14525.
   PubMed Web of Science ®Google Scholar
• Krishnan E, Steinman TI. Reduced glomerular function and prevalence of gout: NHANES 2009-10. PLoS One. 2012;7(11):e50046.
   PubMed Web of Science ®Google Scholar
• Suliman ME, Johnson RJ, García-López E, et al. J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis off J Natl Kidney Found. 2006;48(5):761–771.
   PubMed Web of Science ®Google Scholar
• Chonchol M, Shlipak MG, Katz R, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis off J Natl Kidney Found. 2007;50(2):239–247.
   PubMed Web of Science ®Google Scholar
• Madero M, Sarnak MJ, Wang X, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis off J Natl Kidney Found. 2009;53(5):796–803.
   PubMed Web of Science ®Google Scholar
• Toyoki D, Shibata S, Kuribayashi-Okuma E, et al. Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2. Am J Physiol Renal Physiol. 2017;313(3):F826–F834.
   PubMed Web of Science ®Google Scholar
• Sorensen LF. Gout secondary to chronic renal disease: studies on urate metabolism. Ann Rheum Dis. 1980;39(5):424–430.
   PubMed Web of Science ®Google Scholar
• Prasad Sah OS, Qing YX. Associations between hyperuricemia and chronic kidney disease: a review. Nephrourol Mon. 2015;7(3):e27233.
   Google Scholar
• Roncal-Jimenez C, García-Trabanino R, Barregard L, et al. Heat stress nephropathy from exercise-induced uric acid crystalluria: a perspective on mesoamerican nephropathy. Am J Kidney Dis off J Natl Kidney Found. 2016;67(1):20–30.
   PubMed Web of Science ®Google Scholar
• Martillo MA, Nazzal L, Crittenden DB. The crystallization of monosodium urate. Curr Rheumatol Rep. 2014;16(2):400.
   PubMed Web of Science ®Google Scholar
• Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem. 1991;266(13):8604–8608.
   PubMed Web of Science ®Google Scholar
• Kang D-H, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13(12):2888–2897.
   PubMed Web of Science ®Google Scholar
• Fine LG, Orphanides C, Norman JT. Progressive renal disease: the chronic hypoxia hypothesis. Kidney Int Suppl. 1998;65:S74–8.
   PubMedGoogle Scholar
• Kang D-H. Hyperuricemia and progression of chronic kidney disease: role of phenotype transition of renal tubular and endothelial cells. Contrib Nephrol. 2018;192:48–55.
   PubMed Web of Science ®Google Scholar
• Asakawa S, Shibata S, Morimoto C, et al. Podocyte injury and albuminuria in experimental hyperuricemic model rats. Oxid Med Cell Longev. 2017;2017:3759153.
   PubMed Web of Science ®Google Scholar
• Stull LB, Leppo MK, Szweda L, et al. Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res. 2004;95(10):1005–1011.
   PubMed Web of Science ®Google Scholar
• Naumova AV, Chacko VP, Ouwerkerk R, et al. Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts. Am J Physiol Heart Circ Physiol. 2006;290(2):H837–43.
   PubMed Web of Science ®Google Scholar
• Cappola TP, Kass DA, Nelson GS, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 2001;104(20):2407–2411.
   PubMed Web of Science ®Google Scholar
• Hirsch GA, Bottomley PA, Gerstenblith G, et al. Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts. J Am Coll Cardiol. 2012;59(9):802–808.
   PubMed Web of Science ®Google Scholar
• Alem MM. Allopurinol and endothelial function: a systematic review with meta-analysis of randomized controlled trials. Cardiovasc Ther. 2018;36:e12432.
   PubMed Web of Science ®Google Scholar
• Kanbay M, Siriopol D, Nistor I, et al. Effects of allopurinol on endothelial dysfunction: a meta-analysis. Am J Nephrol. 2014;39(4):348–356.
   PubMed Web of Science ®Google Scholar
• Badve SV, Pascoe EM, Tiku A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020;382(26):2504–2513. Internet]. Available from.
   PubMed Web of Science ®Google Scholar
• Doria A, Galecki AT, Spino C, et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med. 2020 Internet]. ;382:2493–2503. An analysis from the MECKI score research group Available from;(26):… .
   PubMed Web of Science ®Google Scholar
• Givertz MM, Anstrom KJ, Redfield MM, et al. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) Study. Circulation. 2015;131(20):1763–1771.
   PubMed Web of Science ®Google Scholar
• Hare JM, Mangal B, Brown J, et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol. 2008;51(24):2301–2309.
   PubMed Web of Science ®Google Scholar
• Nasr G, Maurice C. Allopurinol and global left myocardial function in heart failure patients. J Cardiovasc Dis Res. 2010;1(4):191–195.
   PubMedGoogle Scholar
• Alem MM, Alshehri AM, Cahusac PM, et al. Effect of xanthine oxidase inhibition on arterial stiffness in patients with chronic heart failure. Clin Med Insights Cardiol. 2018;12:1179546818779584.
   Web of Science ®Google Scholar
• Greig D, Alcaino H, Castro PF, et al. Xanthine-oxidase inhibitors and statins in chronic heart failure: effects on vascular and functional parameters. J Hear lung Transplant Off Publ Int Soc Hear Transplant. 2011;30(4):408–413.
   PubMed Web of Science ®Google Scholar
• Gavin AD. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart. 2005;91(6):749–753.
   PubMed Web of Science ®Google Scholar
• Cingolani HE, Plastino JA, Escudero EM, et al. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: la plata study. J Card Fail. 2006;12(7):491–498. .
   PubMed Web of Science ®Google Scholar
• Tamariz L, Hare JM. Xanthine oxidase inhibitors in heart failure: where do we go from here? Circulation. 2015;131(20):1741–1744.
   PubMed Web of Science ®Google Scholar
• George J, Carr E, Davies J, et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114(23):2508–2516.
   PubMed Web of Science ®Google Scholar
• Gotsman I, Keren A, Lotan C, et al. Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival. J Card Fail. 2012;18(9):694–701.
   PubMed Web of Science ®Google Scholar
• Cicero AFG, Cosentino ER, Kuwabara M, et al. Effects of allopurinol and febuxostat on cardiovascular mortality in elderly heart failure patients. Intern Emerg Med. 2019;14(6):949–956.
   PubMed Web of Science ®Google Scholar
• Foody J, Turpin RS, Tidwell BA, et al. Major cardiovascular events in patients with gout and associated cardiovascular disease or heart failure and chronic kidney disease initiating a xanthine oxidase inhibitor. Am Heal Drug Benefits. 2017;10:393–401.
   PubMed Web of Science ®Google Scholar
• Su C-Y, Shen L-J, Hsieh S-C, et al. Comparing cardiovascular safety of febuxostat and allopurinol in the real world: a population-based cohort study. Mayo Clin Proc. 2019;94(7):1147–1157.
   PubMed Web of Science ®Google Scholar
• White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200–1210
   PubMed Web of Science ®Google Scholar
• Mackenzie IS, Ford I, Nuki G, et al., Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 396(10264): 1745–1757. 2020.
   PubMed Web of Science ®Google Scholar
• Yokota T, Fukushima A, Kinugawa S, et al. Randomized trial of effect of urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia (LEAF-CHF). Int Heart J. 2018;59(5):976–982. .
   PubMed Web of Science ®Google Scholar
• Sakuma M, Toyoda S, Arikawa T, et al. The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol. Clin Exp Nephrol. 2018;22(6):1379–1386.
   PubMed Web of Science ®Google Scholar
• BRONSKY D, DUBIN A, DS KUSHNER. Diuretic action of benemid; its effect upon the urinary excretion of sodium, chloride, potassium and water in edematous subjects. Am J Med. 1955;18(2):259–266.
   PubMed Web of Science ®Google Scholar
• Koch SE, Gao X, Haar L, et al. Probenecid: novel use as a non-injurious positive inotrope acting via cardiac TRPV2 stimulation. J Mol Cell Cardiol. 2012;53(1):134–144. .
   PubMed Web of Science ®Google Scholar
• Robbins N, Gilbert M, Kumar M, et al. Probenecid improves cardiac function in patients with heart failure with reduced ejection fraction in vivo and cardiomyocyte calcium sensitivity in vitro. J Am Heart Assoc. 2018;7(2):7.
   Web of Science ®Google Scholar
• Kim SC, Neogi T, Kang EH, et al. Cardiovascular risks of probenecid versus allopurinol in older patients with gout. J Am Coll Cardiol. 2018;71(9):994–1004.
   PubMed Web of Science ®Google Scholar
• Bardin T, Keenan RT, Khanna PP, et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Di. Available from. 2017;76(5):811– 820. Internet.
   PubMed Web of Science ®Google Scholar
• Nakashima M, Uematsu T, Kosuge K, et al. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 1992;42(3):333–335.
   PubMed Web of Science ®Google Scholar
• Burnier M, Rutschmann B, Nussberger J, et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension. 1993;22(3):339–347.
   PubMed Web of Science ®Google Scholar
• Hamada T, Ichida K, Hosoyamada M, et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens. 2008;21(10):1157–1162.
   PubMed Web of Science ®Google Scholar
• Khan M, Khan RA, Islam F, et al. To study the efficacy of Losartan on urinary uric acid excretion in Thiazide induced hyperuricemic and hypertensive patients. Pak J Pharm Sci. 2011;24(4):583–587.
   PubMed Web of Science ®Google Scholar
• Fan Y, Wei F, Lang Y, et al. Losartan treatment for hypertensive patients with hyperuricaemia in Chinese population: a meta-analysis. J Hypertens. 2015;33(4):681–688. discussion 689.
   PubMed Web of Science ®Google Scholar
• Høieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65(3):1041–1049.
   PubMed Web of Science ®Google Scholar
• Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374(9704):1840–1848. .
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869.
   PubMed Web of Science ®Google Scholar
• Mogensen UM, Køber L, Jhund PS, et al., Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. Eur J Heart Fail. 20(3): 514–522. 2018. .
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. .
   PubMed Web of Science ®Google Scholar
• Mc Causland FR, Lefkowitz MP, Claggett B, et al. Angiotensin-Neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction. Circulation. 2020;142(13):1236–1245.
   PubMed Web of Science ®Google Scholar
• Uthman L, Baartscheer A, Bleijlevens B, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia. 2018;61(3):722–726. .
   PubMed Web of Science ®Google Scholar
• Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014;35(7):391–404.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xu L, Tian D, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level:a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20(2):458–462.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446.
   PubMed Web of Science ®Google Scholar
• Bailey CJ. Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes Obes Metab. 2019;21(6):1291–1298.
   PubMed Web of Science ®Google Scholar
• McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. In: Bonow RO, editor. JAMACardiology. 2020.
   Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. .
   PubMed Web of Science ®Google Scholar
• Lytvyn Y, Bjornstad P, Udell JA, et al., Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 136(17): 1643–1658. 2017. .
   PubMed Web of Science ®Google Scholar
• De MG, Cassone-Faldetta M, Bellini C, et al. Role of plasma and urinary endothelin-1 in early diabetic and hypertensive nephropathy. Am J Hypertens. 1998;11(8):983–988.
   PubMed Web of Science ®Google Scholar
• Rabelink TJ, Kaasjager KAH, Boer P, et al. Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int. Internet]. 1994;46(2):376–381.
   PubMed Web of Science ®Google Scholar
• Mann JFE, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010;21(3):527–535.
   PubMed Web of Science ®Google Scholar
• Wenzel RR, Littke T, Kuranoff S, et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol. 2009;20(3):655–664.
   PubMed Web of Science ®Google Scholar
• De Zeeuw D, Coll B, Andress D, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol. 2014;25(5):1083–1093.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Parving -H-H, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019;393:1937–1947.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
   PubMed Web of Science ®Google Scholar